Stormi Raines
Physician Assistant · West Salem, ILNPI 1558880872
Payments from drug & device makers
Across 158 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$491
- Merck$409
- Novo Nordisk$361
- Novartis$341
- Lilly USA, LLC$227
- Boehringer Ingelheim$148
- plus $799 from 20 others
What the payments were for
- Food & beverage$2,775100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $491 |
| Merck | 23 | $409 |
| Novo Nordisk | 27 | $361 |
| Novartis | 17 | $341 |
| Lilly USA, LLC | 14 | $227 |
| Boehringer Ingelheim | 7 | $148 |
| Mylan Specialty L.p. | 6 | $117 |
| Organon | 2 | $88 |
| GSK | 6 | $79 |
| Johnson & Johnson | 4 | $75 |
| Amarin Pharma, Inc. | 3 | $50 |
| Amgen | 3 | $48 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Bayer | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Exact Sciences | 2 | $29 |
| Boston Scientific | 1 | $27 |
| Corcept Therapeutics | 1 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| AbbVie | 1 | $20 |
| Verona Pharma, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Athena Bioscience, LLC | 1 | $11 |
How this compares
$2,775 in reported general payments places this provider in the 85th percentile of 3,912 physician assistant providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 48 | $60,474 |
| MounjaroTirzepatide | 32 | $48,680 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $42,202 |
| EliquisApixaban | 22 | $22,603 |
| XareltoRivaroxaban | 14 | $12,976 |
| VascepaIcosapent Ethyl | 11 | $7,024 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,217 |
| LinzessLinaclotide | 11 | $5,841 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 68 | $2,625 |
| Sucralfate | 22 | $1,670 |
| Gabapentin | 57 | $1,396 |
| Metoprolol Succinate | 71 | $1,286 |
| Mirtazapine | 51 | $1,279 |
| Atorvastatin Calcium | 144 | $1,189 |
| Losartan Potassium | 95 | $1,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $148 | $60,47448 claims |
| Lilly USA, LLCMounjaro | $227 | $48,68032 claims |
| GSKTrelegy Ellipta | $79 | $42,20241 claims |
| Johnson & JohnsonXarelto | $75 | $12,97614 claims |
| AbbVieLinzess | $20 | $5,84111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,912 physician assistant providers in Illinois.
Other physician assistant in West Salem
- Andrew MastroChicago$419K
- Christopher AricoSkokie$407K
- Karlijn BurridgeWestmont$144K
- Ian MackeySkokie$135K
- Stephanie TraceyItasca$122K
- Olabimpe PhilipsAddison$103K
- Renata BlockChicago$103K
- Margaret RomanoChicago$82K
- Christina StarksChicago$77K
- Darrel CutlerHerrin$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.